指南与共识妇科

妇科肿瘤中建立腹腔热灌注化疗项目的指南

A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology.
指南 / 共识 · Gynecol Oncol · 2020-07-02

本文基于高容量三级医疗中心的经验,综述了在妇科肿瘤中建立腹腔热灌注化疗(HIPEC)项目的循证建议,涵盖多学科团队建设、设备要求、操作流程、药物方案及术中监测,并指出支持最佳方案的证据有限。

要点

  • 建立HIPEC项目需多学科团队,包括妇科肿瘤科、麻醉科、护理、灌注师和药师。
  • 灌注液为等渗晶体液加化疗药,总量3-6 L,目标温度41-43 °C。
  • 使用顺铂时,应在化疗前1小时给予呋塞米和甘露醇以保证充分利尿。

核心结论

  • 本文基于高容量三级医疗中心的经验,描述了指导实施HIPEC项目的循证建议。
  • 支持上皮性卵巢癌患者在减瘤手术时最佳HIPEC方案的证据有限。

研究设计与样本

  • 本文为综述,基于高容量三级医疗中心的经验,描述指导实施HIPEC项目的循证建议。

主要发现

  • 建立HIPEC项目需要多学科团队,包括妇科肿瘤科医生、麻醉科、护理、灌注师和药师。
  • 团队成员需接受HIPEC方案、有毒废物和溢出管理以及个人防护装备(PPE)的教育。
  • 所需设备包括化疗认证的PPE和HIPEC泵,泵连接置于腹腔内的流入和流出导管。
  • 术中灌注3-6 L由等渗晶体液载体和所选化疗药组成的高温灌注液,目标温度41-43 °C。
  • 在HIPEC输注前,手术团队必须与麻醉科和药房沟通。

关键数值与推荐

  • 接受顺铂HIPEC的患者,应在化疗前1小时给予呋塞米和甘露醇以确保充分利尿。
  • 可考虑使用硫代硫酸钠进行肾脏保护(van Driel等,n.d. [3])。
  • 本中心在HIPEC输注前采用多药预用药方案以减少过敏反应、肾毒性和术后恶心呕吐。
  • 本中心倾向于使用顺铂100 mg/m2单药或联合紫杉醇135-175 mg/m2,总灌注时间90分钟。

临床怎么用

  • 术中需密切关注温度和林格控制,因为可能发生高血糖、乳酸酸中毒和低钾血症等电解质紊乱。
  • 持续监测患者并积极处理HIPEC期间出现的异常,对降低患者发病率和死亡率至关重要。
  • 本研究中心的做法是:在HIPEC输注前采用多药预用药方案。
  • 本研究中心的做法是:倾向于使用顺铂100 mg/m2单药或联合紫杉醇135-175 mg/m2,总灌注时间90分钟。

局限性

  • 支持上皮性卵巢癌患者在减瘤手术时最佳HIPEC方案的证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) may be used to treat peritoneal based malignancies, such as epithelial ovarian cancer (EOC). Despite results of clinical trials supporting an increasing indication for HIPEC in EOC, concerns have existed regarding morbidity and challenges with initiating HIPEC at an institutional level. The objective of this review is to describe evidence-based recommendations to guide implementation of a HIPEC program, following our experience at a high-volume tertiary care center. Establishing a HIPEC program requires building a multi-disciplinary team, including gynecologic oncologists, anesthesia, nursing, perfusionists and pharmacists. Team members require education regarding HIPEC protocols, toxic waste and spill management, and personal protective equipment (PPE). Required equipment includes chemotherapy certified PPE and a HIPEC pump which is connected to inflow and outflow catheters placed within the peritoneal cavity. During the procedure, 3-6 L of a hyperthermic perfusate, composed of a isotonic crystalloid vehicle and the chemotherapy of choice, is infused through the peritoneal cavity with goal temperature of 41-43 °C. Prior to HIPEC infusion, surgical teams must communicate with anesthesia and pharmacy. In patients receiving HIPEC with cisplatin, furosemide and mannitol should be administered one hour prior to chemotherapy to ensure adequate diuresis. Sodium thiosulfate may also be considered for renal protection (van Driel et al., n.d. [3]). We utilize a multi-agent pre-medication protocol prior to HIPEC infusion to reduce hypersensitivity reactions, renal toxicity and post-operative nausea and vomiting. Limited data exists to support the optimal regimen for HIPEC at the time of CRS in women with EOC. From our experience, we favor use of cisplatin 100 mg/m2 alone or in combination with paclitaxel 135-175 mg/m2 with 90 min of total perfusion time. Close attention to temperature and glycemic control is essential during the procedure, as electrolyte derangements including hyperglycemia, lactic acidosis and hypokalemia may occur. Continuous patient monitoring and proactive management of abnormalities that arise during HIPEC is imperative to decrease patient morbidity and mortality.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chambers LM, Costales AB, Crean-Tate K, et al. A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology. Gynecol Oncol. 2020. PMID: 32624234. doi:10.1016/j.ygyno.2020.06.487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。